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ABSTRACT
Regimen-related toxicity (RRT) is a frequent cause of morbidity and mortality after allogeneic hematopoietic
stem cell transplantation (HSCT). In this pilot study, we examined the feasibility and potential efficacy of
administering a fixed combination of agents as a novel approach to reducing RRT in children undergoing
HSCT. Thirty-seven patients were treated with ursodeoxycholic acid, folinic acid, vitamin E, and parenteral
nutrition titrated to measured energy expenditure in the peritransplantation period. Outcomes were compared
with those in historical controls (n  131). Compliance with oral ursodeoxycholic acid and vitamin E of at least
90% was achieved in a mean of 86% (95% confidence interval, 75%-97%) of patients. In the study group, we
observed (1) reduced prevalence and severity of mucositis (P  .008 and .004, respectively); (2) less severe
hepatic toxicity (P  .007); and (3) shorter time to engraftment (P  .02) compared with the control group.
These benefits appeared most pronounced among high-risk patients. The administration of this regimen,
including oral medications, is feasible during the peritransplantation period, and it is well tolerated. The
decreased RRT observed in comparison to historical controls suggests that combination approaches deserve
exploration as a means of reducing the morbidity of HSCT.
© 2004 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Regimen-related toxicity (RRT) remains one of
he most common causes of peritransplantation mor-
ality [1-8]. For example, RRT accounts for 20% to
0% of transplant-related mortality among patients
ndergoing unrelated donor hematopoietic stem cell
ransplantation (HSCT) for acute lymphoblastic leu-
emia (ALL) [3-5].
Veno-occlusive disease (VOD) of the liver and
diopathic pneumonia syndrome, which occur in 5% r
B&MTo 60% and 3% to 15% of HSCT patients, respec-
ively, are sporadic early RRT syndromes with high
ortality rates [1,2]. Poor outcome has also been
inked to less dramatic toxicity syndromes. In one
ulticenter study, severe oral mucositis was associated
ith a nearly 4-fold increase in 100-day mortality [9].
n a review of 272 patients, a doubling of serum
reatinine in the ﬁrst 21 days after HSCT was asso-
iated with a 2- to 4-fold increase in mortality [10].
One approach to globally diminishing RRT is to
educe the intensity of the conditioning regimen. This
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6as been pursued with some success among older
SCT recipients [11,12] and in certain high-risk pe-
iatric groups [11,13]. Another approach is to develop
nterventions to counter speciﬁc RRTs. Examples in-
lude the use of lung shields to limit pulmonary ex-
osure to total body irradiation [14] and hyperhydra-
ion and mesna to prevent hemorrhagic cystitis after
yclophosphamide administration [15].
No single agent capable of reducing multiple man-
festations of RRT has yet been identiﬁed. However, a
umber of agents with apparently different mecha-
isms of action had been studied at the time this study
as initiated. Pilot study data suggested efﬁcacy of
rsodeoxycholic acid (UDCA) in decreasing the inci-
ence of hepatic VOD [16] and of folinic acid, admin-
stered after methotrexate used for graft-versus-host
isease (GVHD) prophylaxis, in accelerating engraft-
ent and reducing mucositis and hepatic toxicity [17].
n addition, serum levels of antioxidants had been
hown to decline markedly after conditioning therapy
18], and evidence suggested that vitamin E adminis-
ration could attenuate chemotherapy-induced mu-
ositis and hemolysis [19,20]. Finally, reduction of
arenteral energy and protein intake after HSCT was
ssociated with better metabolic homeostasis [21].
We hypothesized that these interventions would
ave nonoverlapping toxicities and might, in combi-
ation, have (1) additive effects on endothelial and
ucosal health, resulting in decreased RRT in the ﬁrst
00 days after transplantation, and (2) sufﬁcient effect
o be efﬁciently evaluated within the constraints of
xpected accrual at a single pediatric program. How-
ver, the feasibility of delivering therapy by the enteral
oute to children undergoing HSCT was unknown. In
his study, our primary objective was to determine the
easibility of oral administration of UDCA and vita-
in E to medically unstable children in the peritrans-
lantation period. Our secondary objective was to
ompare the prevalence of RRT among the 37 pa-
ients treated with UDCA, folinic acid, vitamin E, and
arenteral nutrition (PN) titrated to provide 100% of
easured resting energy expenditure (REE) with the
revalence of RRT observed in 131 consecutive his-
orical controls.
ATIENTS AND METHODS
ubject and Transplant Characteristics
A total of 37 subjects undergoing allogeneic
SCT at the Children’s Hospital in Boston were
nrolled between June 1998 and June 2000. Subjects
ere study-eligible if they had not undergone prior
ransplantation and were to receive a bone marrow
ransplant with a myeloablative conditioning regimen
nd 1 of 2 standard GVHD prophylaxis regimens.
hey were excluded if they were enrolled on an ex- w
36erimental treatment protocol or a study with con-
icting guidelines for supportive care. Of a total of 80
atients receiving allogeneic HSCT in this period, 43
ere eligible. Six subjects and/or their parents de-
lined participation in the study; 37 were enrolled. We
topped enrolling patients in the study group when
he Data and Safety Monitoring Board advised us that
he feasibility of administering the combination of
upportive care agents being studied had been deter-
ined. Controls (n  131) were consecutive patients
ho underwent transplantation between 1995 (when
tandard institutional conditioning and GVHD pro-
hylaxis regimens were implemented) and 2000 (when
he study was terminated) and who would have met
he eligibility criteria. The institutional review boards
f Dana-Farber Cancer Institute and Children’s Hos-
ital Boston approved the study, and all enrolled pa-
ients and their guardians provided informed consent
nd assent, if applicable.
Patient characteristics are shown in Table 1. Sub-
ects were divided into low- and high-risk groups
ccording to disease and disease status, including di-
gnoses that are not accounted for in published crite-
ia based on hematologic malignancies alone. Risk for
RT was determined a priori. Patients with ALL in
rst (CR1) or second (CR2) complete remission, acute
yeloid leukemia in CR1, chronic myeloid leukemia
n ﬁrst chronic phase, and aplastic anemia were des-
gnated low risk. All others were designated high risk.
iven the arbitrary nature of risk classiﬁcation, we
epeated all risk-stratiﬁed analyses with patients with
LL in CR2 assigned to the high-risk group. The
onor source and degree of HLA matching for low-
nd high-risk patients in the study and control groups
re presented in Table 2.
All patients received T cell–replete bone marrow
rafts. Most patients received a total body irradiation–
ased conditioning regimen (Table 1). All patients
eceived cyclosporine and short-course methotrexate
or GVHD prophylaxis [22]. Patients with unrelated
arrow donors also received intravenous methylpred-
isolone from day 7 to 21 [23]. Hematopoietic growth
actors were not administered as part of routine sup-
ortive care. Recipients who were seropositive for
erpes simplex virus received acyclovir prophylaxis
rom day5 through day 24. If the donor or recipient
as cytomegalovirus seropositive, high-dose acyclovir
rophylaxis was administered [24].
All patients had a dental examination before
SCT to rule out and treat signiﬁcant preexisting
isease of the oral cavity. Pain and nausea were as-
essed throughout the peritransplantation period by
he nursing staff and attending physicians. Pain was
reated with opiate infusions, and antiemetic agents
ere prescribed prophylactically to all patients.
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and severe aplastic anemia. High risk  all other diagnoses.
Reducing RRT in Pediatric HSCT
BB&MTtudy Design and Monitoring
Patients in the study group received combined
herapy with oral UDCA, intravenous folinic acid,
ral vitamin E, and PN matched to measured or cal-
ulated REE. The dose of UDCA was 7.5 mg/kg (60
g/mL of cherry-ﬂavored suspension with a bitter
ftertaste) twice daily for patients 40 kg and 300 mg
tasteless tablet) twice daily for those weighing 40
g. UDCA treatment was initiated 6 to 24 hours
efore conditioning and continued through day 27
fter transplantation or discharge from the HSCT
nit, whichever occurred ﬁrst. Folinic acid was admin-
stered at 5 mg/m2 intravenously every 6 hours for a
otal of 3 doses after the ﬁrst dose of methotrexate, 7
oses after the second methotrexate dose, and 8 doses
fter the third and fourth methotrexate doses. After
ach methotrexate dose, 12 hours elapsed before fo-
inic acid was administered. Vitamin E was adminis-
ered at 8 IU/kg (15 IU/0.3 mL of sweetened suspen-
ion with a bitter aftertaste) once daily for patients
25 kg and 400 IU (tasteless capsule) once daily for
atients weighing 25 kg. Therapy with vitamin E
as commenced 3 to 5 days before conditioning and
ontinued through day 27 after transplantation or
ischarge from the HSCT unit, whichever occurred
rst.
In the study group, PN was commenced when oral
ntake decreased below REE for 5 to 7 days and was
itrated so that total energy intake (enteral and paren-
eral) provided approximately 100% of estimated
EE, or 100% of REE measured by indirect calorim-
try with the Vmax V29 metabolic monitor (Sensor-
edics, Yorba Linda, CA) in cooperative subjects (n
5) [25]. Throughout the study, oral intake was al-
owed ad libitum. PN was discontinued when oral
ntake met REE needs for 2 consecutive days. In
istorical controls, PN was provided, according to
onventional practice, to deliver 130% to 150% of
stimated basal energy needs [26]. Nutritional out-
omes in the study group have recently been pub-
ished [25].
Compliance with doses of UDCA and vitamin E
ntrol Groups
Control Group (n  131)
atch HLA Match HLA Mismatch
33 4
23 2
20 6
38 5
HLA loci.
leukemia in CR1, chromic myeloid leukemia in ﬁrst chronic phase,able 1. Patient and Transplant Characteristics
Variable
Study Group
(n  37)
Control Group
(n  131)
edian age, y (range) 8 (0.7-19) 8 (0.4-22)
iagnosis, n (%)
ALL 9 (24) 43 (33)
AML 4 (11) 35 (25)
CML 5 (14) 7 (5)
MDS 3 (8) 17 (13)
JMML 1 (3) 1 (1)
NHL 1 (3) 4 (3)
SAA 7 (19) 14 (11)
THAL — 2 (2)
Storage disease 1 (3) 4 (3)
WAS 3 (8) 1 (1)
HLH 2 (5) 1 (1)
Other* 1 (3) 4 (3)
onor, n (%)
Related 13 (35) 62 (47)
Unrelated 24 (65) 69 (53)
HLA-matched† 35 (95) 114 (87)
HLA-mismatched 2 (5) 17 (13)
adiation-containing conditioning,
n (%)
33 (89) 113 (86)
ean nucleated cell dose
108/kg (mean  SE)
5.6  3.4
(n  36)
5.1  3.2
(n  61)
SV serostatus, n (%)
Positive 16 (43) 61 (47)
Negative 20 (54) 67 (51)
Unknown 1 (3) 3 (2)
isk assignment, n (%)
Low risk 20 (54) 63 (48)
High risk 17 (46) 68 (52)
LL indicates acute lymphoblastic leukemia; AML, acute myeloid
leukemia; CML, chronic myeloid leukemia; MDS, myelodys-
plastic syndrome; JMML, juvenile myelomonocytic leukemia;
NHL, non-Hodgkin lymphoma; SAA, severe aplastic anemia;
THAL, thalassemia major; WAS, Wiskott-Aldrich syndrome;
HLH, hemophagocytic lymphohistiocytosis; HSV, herpes sim-
plex virus.
Study group: amegakaryocytic thrombocytopenic purpura (AMT;
n  1). Control group: AMT (n  1), osteopetrosis (n  1),
myeloproliferative syndrome (n  1), and Diamond-Blackfan
anemia (n  1).
HLA match  high-resolution molecular match at 6 of 6 (A, B,
and DR) HLA loci.
Low risk  ALL in CR1 or CR2, AML in CR1, CML in ﬁrst
chronic phase, and SAA. High-risk  all other diagnoses.able 2. Donor Source, HLA Matching, and Risk Status within Study and Co
Variable
Study Group (n  37)
HLA Match* HLA Mism
elated donor
Low risk† 10 0
High risk† 2 1
nrelated donor
Low risk 10 0
High risk 13 1
HLA match  high-resolution molecular match at 6 of 6 (A, B, and DR)
Low risk  acute lymphoblastic leukemia in CR1 or CR2, acute myeloid637
w
u
s
c
d
c
i
a
r
p
p
d
s
3
o
l
n
t
(
v
H
b
g
b
C
o
w
r
p
t
u
f
C
a
t
m
b
p
m
v
d
a
p
u
c
d
v
c
ﬁ
[
t
a
B
m
H
c
s
V
o
g
b
i
a
i
d
g
F
o
r
f
P
a
K
i
e
m
t
p
t
a
c
m
t
a
t
i
p
C
9
a
a
w
2
s
t
(
R
p
c
I. Thornley et al.
6as tracked from admission to the inpatient HSCT
nit through day 27 after HSCT (or discharge, if
ooner). Nurses administering the medications re-
orded patient compliance on preprinted forms. A
edicated research nurse reviewed these forms daily,
onﬁrming the fate of each intended dose and record-
ng reasons for noncompliance. One nurse on the unit
ssumed a central role in explaining the study and
eviewing strategies to promote compliance with her
eers. The importance of parental support for com-
liance was explained clearly to each family before and
uring their involvement.
Serum samples were obtained from patients in the
tudy group before the ﬁrst dose of vitamin E and on
occasions at weekly intervals thereafter. Serum levels
f vitamin E were measured by high-performance
iquid chromatography, as reported in part [25].
End-organ toxicity (hepatic, pulmonary, and re-
al) was monitored and scored according to Na-
ional Cancer Institute common toxicity criteria
CTC) [27] daily while inpatient and at outpatient
isits (at least every 2 weeks) through day 100 after
SCT. Oral mucositis severity was assessed daily
y the attending physician on the HSCT unit and
raded according to adapted CTC for stomatitis in
one marrow transplant patients. According to the
TC, the use of PN automatically implies mucositis
f at least grade 3 severity [27]. In our patients, PN
as provided for a number of reasons, including
efusal to eat because nausea or pain, and to sup-
lement oral intake to reach energy goals. Because
he institution of PN could never reliably be attrib-
ted to mucositis alone, we discarded use of PN
rom the mucositis grading system. The adapted
TC are as follows: grade 0, no pain and normal-
ppearing mucosa; grade 1, painless ulcers, ery-
hema, or mild soreness with no lesions; grade 2,
ucositis with painful erythema, edema, or ulcers,
ut able to swallow secretions; grade 3, mucositis
reventing swallowing of secretions; and grade 4,
ucositis requiring tracheal intubation.
Patients were evaluated for hepatic VOD as pre-
iously described [2]. The date of engraftment was
eﬁned as the ﬁrst of 3 consecutive days with an
bsolute neutrophil count 500/L, and the date of
latelet recovery was deﬁned as the ﬁrst of 7 consec-
tive days with a transfusion-independent platelet
ount 20000/L. All engrafted patients were
eemed to be at risk for acute GVHD; patients sur-
iving beyond day 100 were considered at risk for
hronic GVHD. Acute and chronic GVHD were de-
ned and graded according to standard criteria
28,29]. Additionally, signiﬁcant infectious complica-
ions, dates of relapse and last follow-up, and dates
nd causes of death were recorded. 1
38iostatistical Considerations
Study outcomes were compliance with oral study
edications and RRT in the ﬁrst 100 days after
SCT, time to engraftment, infection, acute and
hronic GVHD, relapse, and event-free and overall
urvival. RRTs of interest were hepatic (including
OD), renal, pulmonary, and oral mucositis. For all
utcomes (except compliance), the study and control
roups were compared before and after stratiﬁcation
y risk status.
Differences between the experimental and histor-
cal control groups with respect to continuous vari-
bles were analyzed by using the Student t test for
ndependent groups or the Wilcoxon rank-sum test,
epending on the distribution of the variable. Cate-
orical variables were compared by using the 2 test or
isher exact test, as appropriate. In the determination
f event-free survival (EFS), events were classiﬁed as
elapse or death from any cause; EFS was established
rom the date of HSCT to the date of the event.
atients not experiencing an event at the time of
nalysis were censored at the time of last contact. The
aplan-Meier method was used to estimate probabil-
ties of relapse, EFS, and overall survival with standard
rrors calculated according to the Greenwood for-
ula. Groups were compared by using the log-rank
est.
We distinguished between “total compliance” (the
roportion of prescribed doses of oral medications
hat were successfully ingested) and “patient compli-
nce” (the proportion of doses offered that were suc-
essfully ingested). If a patient vomited within 30
inutes of the administration of an oral medication,
he ingestion was deemed unsuccessful. Mean total
nd patient compliances were obtained by calculating
he respective proportion for each patient and averag-
ng over patients. Conﬁdence intervals (CIs) for com-
liance within a patient or within a day, as well as the
Is for the proportion of patients who were at least
0% compliant, were obtained by using the normal
pproximation to the binomial distribution. Means
nd standard deviations of serum vitamin E levels
ere calculated, and levels were compared by using
-tailed paired t tests.
All tests of statistical signiﬁcance were 2 sided, and
tatistical signiﬁcance was deﬁned as P  .05. Statis-
ical analyses were performed with SAS-PC software
version 8.0; SAS Institute Inc., Cary, NC).
ESULTS
Study end points were evaluated in 37 enrolled
atients and 131 historical controls. The baseline
haracteristics of the 2 groups are presented in Tables
and 2.
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Reducing RRT in Pediatric HSCT
Bompliance with Oral Study Medications
A total of 3455 doses of UDCA and vitamin E
ere prescribed for the 37 patients in the study group
or a median of 33 days (range, 26-34 days). Of these,
149 were taken and tolerated. The mean total com-
liance was 91.2% (95% CI, 85.8%-96.5%). Of the
06 doses that were not taken, 50 (1.4% of total
rescribed doses) were never offered to the patient,
nd 256 (7.4% of total prescribed doses) were offered
ut not successfully taken. The mean patient compli-
nce was 92.4% (95% CI, 86%-97.8%). The most
ommon reasons for failure to offer a dose were nurs-
ng error and physicians’ orders precluding the admin-
stration of oral medications. The most common rea-
ons for doses not being successfully taken (and for
oncompliance as a whole) were patient refusal and
mmediate postadministration vomiting (data not
hown).
As shown in Figure 1, total compliance90% was
chieved over the course of the study in a mean of
4% (95% CI, 72%-96%) of patients; patient compli-
nce of 90% was seen in 86% (95% CI, 75%-97%)
f patients. There was no discernible difference be-
ween compliance with UDCA and vitamin E. No
elationship between compliance and age, time on
reatment, or maximal mucositis grade could be iden-
iﬁed (data not shown). An effect of sex was detected,
ut this was due entirely to a single female patient
ith particularly poor compliance (data not shown).
Serum levels of vitamin E were 13.9 6.0 mg/dL,
2.7 3.5 mg/dL, 13.6 10.5 mg/dL, and 13.5 6.0
g/dL at baseline, week 1, week 2, and week 3 of the
tudy, respectively. No signiﬁcant differences were
igure 1. Total compliance and patient compliance: numbers of pa
f prescribed doses of oral medications that were successfully inge
uccessfully ingested) with oral ursodeoxycholic acid and vitamin Eoted in paired comparisons. P
B&MTegimen-Related Toxicity
Patients in the study group had both less mucositis
P  .008) and less severe mucositis (P  .004) than
istorical controls (Table 3) and experienced less se-
ere hepatic toxicity (P  .007). There was no differ-
nce between groups in the prevalence or severity of
ulmonary or renal toxicity. The difference in the
revalence of hepatic VOD (3% in the study group
nd 15% in historical controls) was not signiﬁcant
P  .08). When the groups were stratiﬁed according
o risk (Table 4), differences in RRT were most
arked among high-risk patients, with a signiﬁcantly
ower severity of mucositis and a lower prevalence and
everity of hepatic toxicity in the study group. The
nly difference seen among low-risk patients was a
ower prevalence of mucositis in the study group. The
igniﬁcance of differences noted in the risk-stratiﬁed
nalyses was retained when patients with ALL in CR2
ere included in the high-risk, instead of the low-risk,
roup (data not shown). No signiﬁcant toxicity was
ttributable to the study medications.
ngraftment, Infection, GVHD, Relapse, and
urvival
A sustained absolute neutrophil count of
500/L was attained more rapidly in the study
roup, with engraftment occurring at a median of 19
ays (interquartile range [IQR], 17-24 days), com-
ared with 22 days (IQR, 19-27 days; P  .02) in the
ontrols (Table 3). As shown in Table 4, there was a
triking difference in rates of engraftment among
igh-risk patients: 17 days (IQR, 16-18 days) in the
ntervention group versus 21 days (IQR, 18-26 days;
achieving the indicated ranges of total compliance (the proportion
nd patient compliance (the proportion of doses offered that weretients
sted) a .0004) in controls. There was no difference ob-
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6erved among low-risk patients. The signiﬁcance of
he engraftment advantage among high-risk patients
as retained when patients with ALL in CR2 were
ncluded in the high-risk group (data not shown). No
ifferences in platelet recovery were seen between the
tudy group and controls before or after risk stratiﬁ-
ation (Tables 3 and 4).
No signiﬁcant differences were observed in the
revalence or severity of documented bacterial, fun-
able 3. Outcomes in Study and Control Groups
Variable
Stu
eak mucositis grade,* n (%)
0 2
1 7
2 24
3 4
4 0
edian mucositis grade (IQR) 2
ulmonary toxicity grade,* n (%)
0 26
1 4
2 1
3 4
4 0
5 2
edian pulmonary grade (IQR) 0
epatic toxicity grade,* n (%)
0 3
1 11
2 11
3 9
4 2
5 1
edian hepatic grade (IQR) 2
epatic VOD, n (%) 1
enal toxicity grade,* n (%)
0 15
1 13
2 7
3 1
4 1
5 0
edian renal grade (IQR) 1
edian days to ANC >500/L (IQR) 19
edian days to platelets >20 000/L (IQR) 28
cute GVHD grade, n (%)
0 19
I 4
II 4
III 1
IV 3
hronic GVHD, n (%)
Limited 9
Extensive 7
-y EFS  SE (%)
-y OS  SE (%)
QR indicates interquartile range; VOD, veno-occlusive disease; A
event-free survival; OS, overall survival.
According to National Cancer Institute common toxicity criteria
transplantation) [27].al, or viral infections (data not shown) or acute and i
40hronic GVHD (Tables 3 and 4). Relapse of malig-
ancy occurred after transplantation in 6 (26%) of 23
nd 37 (35%) of 107 at-risk patients in the study and
ontrol groups, respectively; the probability of relapse
id not differ signiﬁcantly (P  .2).
There were 11 deaths among the 37 subjects in the
tudy group: 6 from progressive disease and 5 attrib-
ted to HSCT-related causes (multiorgan failure in 3,
ulmonary VOD in 1, and lymphoproliferative disease
oup
)
Control Group
(n  131) P Value
n  131 .008
1 (1)
22 (17)
56 (42)
51 (39)
1 (1)
2 (2-3) .004
n  131 .07
100 (76)
2 (2)
2 (2)
10 (8)
8 (6)
9 (7)
0 (0-0) .70
n  131 .07
4 (3)
21 (16)
33 (25)
49 (37)
23 (18)
1 (1)
3 (2-3) .007
19 (15) .08
n  131 .50
68 (52)
34 (26)
14 (11)
5 (4)
9 (7)
1 (1)
0 (0-1) .90
21.5 (19-27) .02
8.5) 27 (23-35) .30
n  120 .30
61 (51)
15 (13)
17 (14)
25 (21)
2 (2)
n  103 .10
12 (12)
17 (17)
49  4 .03
53  4 .05
bsolute neutrophil count; GVHD, graft-versus-host disease; EFS,
) (for mucositis, adapted from CTC for stomatitis/bone marrowdy Gr
(n  37
n  37
(5)
(19)
(65)
(11)
(0)
(2-2)
n  37
(70)
(11)
(3)
(11)
(0)
(5)
(0-1)
n  37
(8)
(30)
(30)
(24)
(5)
(3)
(1-3)
(3)
n  37
(41)
(35)
(19)
(3)
(3)
(0)
(0-1)
(17-24)
(17.5-3
n  37
(51)
(11)
(11)
(3)
(8)
n  34
(26)
(21)
70  8
70  8
NC, a
(CTCn 1). Of 63 deaths among 131 control subjects, 35
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Reducing RRT in Pediatric HSCT
Bere due to progressive disease and 27 to HSCT-
elated causes (multiorgan failure in 10, respiratory
ailure in 8, sepsis in 5, GVHD in 2, CMV disease in
, and hemorrhagic myocarditis in 1); the cause for 1
s unknown.
The probabilities of EFS and overall survival at 4
ears were 70%  8% and 70%  8% in the study
roup and 49% 4% and 53% 4% among controls
able 4. Outcomes in Risk Groups
Variable
Low Ri
Study Group
(n  20)
Contro
(n 
eak mucositis grade, n (%)
0 2 (10)
1 3 (15) 12 (
2 12 (60) 29 (
3 3 (15) 22 (
4 0
edian mucositis grade (IQR) 2 (1.5-2) 2 (
ulmonary toxicity grade, n (%)
0 14 (70) 53 (
1 3 (15) 1 (
2 1 (5) 1 (
3 1 (5) 3 (
4 0
5 1 (5) 5 (
edian pulmonary grade (IQR) 0 (0-1) 0 (
epatic toxicity grade, n (%)
0 1 (5) 1 (
1 4 (20) 11 (
2 8 (40) 23 (
3 6 (30) 19 (
4 1 (5) 9 (
5 0
edian hepatic grade (IQR) 2 (1.5-3) 2 (
o. with hepatic VOD (%) 0 5 (
enal toxicity grade, n (%)
0 6 (30) 33 (
1 9 (45) 19 (
2 4 (20) 8 (
3 0 1 (
4 1 (5) 2 (
5 0
edian renal grade (IQR) 1 (0-1.5) 0 (
ays to ANC >500/L (IQR) 23.5 (18.5-27) 22 (
ays to platelets >20 000/L (IQR) 29 (27-41) 28 (
cute GVHD grade, n (%)
0 12 (60) 34 (
I 2 (10) 7 (
II 3 (15) 7 (
III 1 (5) 12 (
IV 2 (10) 1 (
hronic GVHD, n (%)
Limited 4 (21) 7 (
Extensive 4 (21) 10 (
-y EFS  SE (%) 75  10 63
-y OS  SE (%) 75  10 70
QR, interquartile range; VOD, veno-occlusive disease; ANC, abso
survival; OS, overall survival.
Low-risk  acute lymphoblastic leukemia in CR1 or CR2, acute m
and severe aplastic anemia. High-risk  all other diagnoses.P  .03 and .05, respectively; Table 3). Four-year c
B&MTFS among high-risk patients (Table 4) was 65% 
2% in the study group and 37%  6% in controls
P  .04).
ISCUSSION
We have shown that compliance with oral medi-
High Risk*
p
P Value
Study Group
(n  17)
Control Group
(n  68) P Value
.03 .06
0 1 (1)
4 (24) 10 (15)
12 (70) 27 (40)
1 (6) 29 (43)
0 1 (1)
.07 2 (2-2) 2 (2-3) .03
.10 .50
12 (71) 47 (69)
1 (6) 1 (1)
0 1 (1)
3 (18) 7 (10)
0 8 (12)
1 (6) 4 (6)
.90 0 (0-1) 0 (0-3) .60
.70 .045
2 (12) 3 (4)
7 (41) 10 (15)
3 (18) 10 (15)
3 (18) 30 (44)
1 (6) 14 (21)
1 (6) 1 (1)
.30 1 (1-3) 3 (2-3) .01
.30 1 (6) 14 (21) .30
.50 .70
9 (53) 35 (51)
4 (23) 15 (22)
3 (18) 6 (9)
1 (6) 4 (6)
0 7 (10)
0 1 (1)
.20 0 (0-1) 0 (0-2) .40
.98 17 (16-18) 21 (18-26) .0004
.80 17.5 (16-31.5) 27 (23-34) .20
.30 .90
7 (41) 27 (46)
2 (12) 8 (14)
3 (18) 10 (17)
4 (24) 13 (22)
1 (6) 1 (2)
.60 .10
5 (33) 5 (11)
2 (20) 7 (15)
.30 65  12 37  6 .04
.50 65  12 38  6 .06
utrophil count; GVHD, graft-versus-host disease; EFS, event-free
leukemia in CR1, chronic myeloid leukemia in ﬁrst chronic phase,sk*
l Grou
63)
0
19)
46)
35)
0
2-3)
84)
2)
2)
5)
0
8)
0-0)
2)
17)
37)
30)
14)
0
2-3)
8)
52)
30)
13)
2)
3)
0
0-1)
19-28)
24-36)
56)
11)
11)
20)
2)
13)
18)
 6
 6
lute ne
yeloidations by pediatric HSCT recipients during the pe-
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6iod of maximal discomfort and high medical acuity
arly after HSCT can be remarkably good. We en-
ountered no signiﬁcant toxicity attributable to the
dministration of the combination of UDCA, folinic
cid, vitamin E, and PN titrated to provide 100% of
esting energy needs in the peritransplantation period.
ur results suggest that this regimen may attenuate
RT, speciﬁcally mucositis and hepatic toxicity, and
esult in a shorter time to engraftment. These beneﬁts
eem to be most marked among high-risk patients.
lthough it is possible that tissue-protecting agents
ould compromise either malignant cell kill or
VHD prophylaxis [30], we did not identify an in-
reased risk of relapse or GVHD in this pilot study.
To our knowledge, no previous studies have pro-
pectively assessed compliance with oral medications
mong such patients. Prospective studies have estab-
ished the feasibility and efﬁcacy of enteral nutrition,
enerally administered by nasogastric tube, in HSCT
atients [31,32]. Investigators have recognized the
eed for multidisciplinary efforts to sustain such ini-
iatives [31-33]. Multidisciplinary effort and the pro-
pective nature of our study may explain the discrep-
ncy between compliance noted in this study and the
etrospective study of Phipps and DeCuir-Whalley
34], who documented a 52% incidence of signiﬁcant
ompliance difﬁculties with oral antibiotics on a pedi-
tric HSCT unit.
Although we did not evaluate the bioavailability of
ral UDCA, multiple published trials demonstrating
n effect of oral UDCA on hepatic functioning
trongly suggest bioavailability in this setting [16,35-
7]. However, we did monitor serum levels of vitamin
. A profound decrease in serum vitamin E levels
uring conditioning therapy and early after HSCT
as been reported [18,38]. Therefore, we believe that
he observed maintenance of preconditioning serum
itamin E levels attests to the bioavailability of orally
dministered medications in our population and is
onsistent with the observed high level of compliance.
There are 2 ways in which the design of this study
imits the strength of its ﬁndings. First, we piloted
hese interventions in a cohort of prospectively en-
olled patients and then compared outcomes with
hose of a large number of consecutive historical con-
rols (some of whom underwent transplantation con-
emporaneously with the study group). This approach
llowed the study to be conducted over a reasonable
eriod of time but introduced the biases of any his-
orically controlled study. Although the controls were
ntentionally selected from a period when the condi-
ioning and supportive care regimens were held con-
tant, potential biases may have arisen from changes in
eferral base, other changes in clinical practice, lack of
linding of treating physicians and study personnel,
nd more assiduous monitoring of study patients com-
ared with historical controls. Second, by hypothesiz- m
42ng that a combination of interventions might be more
ffective than individual agents in decreasing RRT, we
liminated any ability to attribute outcomes to indi-
idual regimen components.
Certainly, all study components could have con-
ributed to the observed outcomes. Reduced amounts
f PN may have led to a reduction in hepatic toxicity,
ecause abnormalities in liver function have been cor-
elated with parenteral overfeeding [39]. Folinic acid
lone has been associated with a shorter time to en-
raftment and less mucositis and hepatic toxicity in
nother historically controlled trial in HSCT recipi-
nts, although no survival advantage was noted [17]. It
s interesting to note that the engraftment advantage
oted in our study group (2-3 days)—none of whom
eceived hematopoietic growth factors after HSCT—is
omparable to that achieved by administering recom-
inant human granulocyte colony-stimulating factor
fter HSCT and was gained at a fraction of the cost
40]. Recent studies have provided evidence that vita-
in E supplementation may attenuate regimen-in-
uced mucositis [41] and have suggested multiple
echanisms by which vitamin E may mitigate cyclo-
porine-induced hepatic and renal toxicity [42,43].
linical trials suggest a role for UDCA in the reduc-
ion of hepatic toxicity after HSCT [35-37], but efﬁ-
acy is not uniform [44].
Our understanding of the mechanism of action of
DCA is evolving. In addition to promoting cholere-
is and displacing hydrophobic and toxic bile acids
hat accumulate during cholestasis, UDCA reduces
he expression of class I major histocompatibility an-
igens on hepatocytes [45]. Ruutu et al. [37] found a
eduction in the incidence of higher-grade acute
VHD in UDCA-treated patients that was not ob-
erved in our study. This might be due to the rela-
ively small numbers of patients studied, interactions
etween UDCA and other medications, or perhaps
he fact that our patients received UDCA for approx-
mately 1 month, as opposed to 3 months in the other
tudy. This same study, which enrolled predominantly
dult HSCT recipients, yielded a survival beneﬁt
olely among low-risk patients [37]. In contrast, there
as a suggestion of a survival beneﬁt in high-risk
atients only in our study. We would speculate that
ne reason for this disparity might be the difference in
ge groups studied: adult high-risk patients are prob-
bly at the greatest risk for RRT and may be least
menable to the effect of mildly effective RRT-spar-
ng agents, whereas pediatric low-risk patients are
robably at least risk for RRT, and their outcome is
ufﬁciently favorable that the effect of mildly effective
RT-sparing agents cannot be discerned. Pediatric
igh-risk patients and adult low-risk patients may in-
ersect with respect to risk for RRT and nonrelapse
ortality and therefore represent populations most
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Bmenable to risk modulation by RRT-sparing inter-
entions such as those evaluated here.
In summary, this pilot study demonstrates that
dministration of the combination of UDCA, folinic
cid, vitamin E, and appropriately targeted PN is
easible and well tolerated. Our analysis also suggests
hat these interventions in aggregate may reduce mu-
ositis and hepatic toxicity and enhance engraftment
mong pediatric HSCT recipients, most notably
mong high-risk patients. We believe that speciﬁc
ombination approaches to supportive care merit eval-
ation in randomized studies, which should include an
rray of outcomes, including cost-effectiveness and
uality of life, as well as efﬁcacy measures.
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